BIOTECH ASSISTANT / FIELD NOTES

Pharmaceutical perspectives on oligonucleotide therapeutics and delivery systems

Academic source · Pharmacological Reviews

Source published: · Event / reporting date: 2025-05-14

Site published: 2026-11-04 · Updated: 2026-11-04

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗

What the paper reports

This review examines RNA species, structure and function, chemical modifications, and delivery systems in the context of therapeutic development. It connects molecular design with stability and distribution and discusses clinical applications available at the time of writing. Its historical approval overview should not be interpreted as a current, exhaustive drug list.

Why this paper is included

Provides a framework for separating payload chemistry from delivery strategy.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

Oligonucleotide Therapeutics & Delivery

Related updates

Vir Biotechnology / Business Wire

Vir schedules Phase 3 elebsiran–tobevibart results for The Liver Meeting

Vir Biotechnology announced that Phase 3 ECLIPSE 1 results for elebsiran plus tobevibart in chronic hepatitis delta will be presented on November 8, with an investor discussion on November 9. Elebsiran is an HBV-targeting siRNA; tobevibart is an antibody. The release announces the forthcoming readout and expanded Phase 2 presentations but does not disclose the Phase 3 numerical results.

Nitto Denko Avecia

Avecia and EnPlusOne agree to evaluate enzymatic RNA manufacturing

Nitto Denko Avecia and EnPlusOne signed an evaluation agreement for the ezRNA enzymatic synthesis platform. The phased program covers proof-of-concept studies, laboratory process evaluation, and technology transfer at Avecia facilities. The platform uses a water-based, template-free process. The agreement evaluates manufacturing feasibility; it does not announce a completed commercial manufacturing contract or a definitive platform license.

Integrated DNA Technologies

IDT and Aldevron launch research-grade base and prime editing RNA tools

IDT and Aldevron launched PE Ultra prime-editor mRNA, chemically modified pegRNAs, and six ABE8e-based editor mRNAs with a parallel screening kit. The companies also described guide-design support and stocked quantities from 20 micrograms to 1 milligram. These are research-use products; the announcement does not establish clinical safety, efficacy, or approval.

Continue your research

Explore company filters, side-by-side comparisons, private bookmarks, and member discussions.

Open free member tools ↗
AI assistant ↗